Verix debuts AI capabilities for its Tovana platform to drive growth in pharmaceutical industry - The EE

Verix debuts AI capabilities for its Tovana platform to drive growth in pharmaceutical industry

Verix, a provider of AI commercial operations enhancement platforms for the pharmaceutical industry, announced the launch of an AI patient finder analysis for its Tovana platform. Tovana is an AI/ML and analytics-powered commercial optimisation platform that provides life science organisations with the ability to harness all the available HCP (health care provider), patient, and market data, while providing continuous, reliable and explainable data-driven insights so pharma companies can optimise their execution and drive growth.

Tovana leverages the power of AI to process anonymised claim level patient longitudinal data, producing in-depth, accurate information at a fraction of the time and price as traditional approaches. This data helps pharma companies streamline their sales and business process and ensure the right patients are getting the right drugs, at the right time.

The platform automatically ingests new data as it arrives, so it is constantly providing up-to-date insights. Tovana optimises execution, enhances transparency, and enables cross-team collaboration. Top industry players are already using the Tovana platform, including GSK, Bayer, Novartis, and Roche.

The “patient finder analysis,” allows for the early identification of new patients with rare diseases based on the AI matching of previous patients with similar journeys. This feature can reduce treatment discontinuity by providing insights into previous – and similar – patient journeys, as well as streamlined operations and increased efficiency by leveraging advanced analytics and data sources for patient optimisation.

Verix has already developed and implemented additional industry use cases on top of the Tovana platform, such as dynamic targeting and segmentation, bottom-up forecasting, channel mix optimisation, and therapeutic landscape analysis. For pharma companies, these use cases optimise customer engagement and strengthen market positioning, leading to revenue increase. In addition, with no-code capabilities, Tovana allows users to develop their own models or utilise out-of-the-box tried and true use cases.

“As we continue to grow, serving more and more customers, we understand the strategic value of building out the category-leading AI capabilities of our platform,” says Doron Aspitz, CEO of Verix. “Tovana’s patient finder feature has the ability to revolutionise the way rare diseases are treated. We know that Tovana’s use cases fill an important gap in pharmaceutical analytics and look forward to continuing to build out the platform’s AI-driven capabilities in the future.”

Follow us and Comment on Twitter @TheEE_io

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.